Minerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016
(Thomson Reuters ONE) -
WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
(NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the
development of innovative therapies to treat central nervous system (CNS)
disorders, today announced that it will present at the JMP Securities Life
Sciences Conference in New York on Tuesday, June 21 at 12:30 p.m. eastern time.
The presentation will be web cast and accessible through the investor relations
section of the Company's web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases. Minerva's proprietary compounds include: MIN-101, which has
completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which
has completed Phase IIa and Phase Ib clinical trials in insomnia and MDD,
respectively; MIN-117, which has completed Phase IIa development for MDD; and
MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common
stock is listed on the NASDAQ Global Market under the symbol "NERV." For more
information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via GlobeNewswire
[HUG#2020676]
Datum: 14.06.2016 - 22:15 Uhr
Sprache: Deutsch
News-ID 477728
Anzahl Zeichen: 2077
contact information:
Town:
Waltham
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Minerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
Minerva Neurosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
